Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function

(2022) Daniel B. Rosoff et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The next generation of triglyceride-lowering drugs

(2020) Laurens F. Reeskamp et al.   CURRENT OPINION IN LIPIDOLOGY

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

(2020) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

(2017) Brian A Ference et al.   EUROPEAN HEART JOURNAL

Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

(2017) Marianne Benn et al.   BMJ-British Medical Journal

Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

(2017) Marianne Benn et al.   BMJ-British Medical Journal

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Common variants associated with plasma triglycerides and risk for coronary artery disease

(2013) Ron Do et al.   NATURE GENETICS